Adenosine signaling: the convergent hub in antidepressant action
1The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology & Optometry, and Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Ophthalmology & Optometry, and Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Abstract:
A groundbreaking study by Yue et al. reveals adenosine signaling as the convergent mechanism underlying the rapid antidepressant effects of both ketamine and electroconvulsive therapy. This discovery not only resolves a longstanding mechanistic puzzle but also opens new therapeutic avenues, including novel ketamine derivatives and nonpharmacological interventions that harness adenosine's antidepressant potential.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Overview
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
G-protein Coupled Receptors


